Explore cutting-edge endometrial cancer research with Novotech CRO's disease report. Learn about new treatments, clinical trials, and future innovations in endometrial cancer care.
Uterine cancer, primarily endometrial cancer, ranks as the fourth leading cause of global gynaecological malignancy-related deaths. Risk factors include extended estrogen exposure, early menarche, late menopause, nulliparity, obesity, hypertension, diabetes, estrogen-only HRT, and genetic syndromes like Lynch and Cowden. Most cases occur in postmenopausal women aged 55-65. Projections indicate a continuous increase in new uterine cancer cases as well as incidence rate, possibly surpassing 600,000 annual new cases by 2044.
Endometrial cancer management integrates surgery, systemic therapy, and radiotherapy, dictated by tumor histopathology and patient factors. NCCN and ESMO guidelines offer tailored recommendations, highlighting multimodal strategies for advanced stages. Hormonal therapy targets lower-grade or recurrent endometrial cancer. Recurrences prompt diverse treatments, including surgery, radiation, or systemic therapy, guided by tumor location and prior treatments. Recent FDA approvals, such as dostarlimab-gxly and pembrolizumab in combination with lenvatinib, expand therapeutic options for advanced and recurrent endometrial cancer. Adaptation of ESMO guidelines for Asian countries underscores the global effort to optimize endometrial cancer care. Multidisciplinary approaches and emerging treatments aim to improve outcomes in endometrial cancer management.
Moving on to prevalence, endometrial cancer poses a significant health burden with nearly 420,370 new cases and 97,720 deaths reported in 2022, globally. Asia recorded the highest incidence, followed by Europe, North America, and rest of the world regions. The country-wise incidence rates showed variations, with Mainland China, the United States, Canada, Russia, Ukraine, and Poland having the highest rates among others. These diverse trends reflect the complex epidemiological landscape of endometrial cancer across the world.
Regarding clinical trials, since 2018, the biotech and biopharma industry initiated over 1200 endometrial cancer trials. North America and Asia-Pacific lead in the number of trials conducted, followed by Europe, while the rest of the world contributes moderately. The United States leads in North America, while Mainland China is prominent in Asia-Pacific. Significant research efforts are also seen in Spain in the European region and Israel in the rest of the world. With respect to patient recruitment trends, Asia-Pacific showed shorter recruitment durations and faster patient recruitment rates in comparison to the United States and Europe.
Next, moving on to the marketed and drug pipeline trends, there are diverse products offered by companies like Merck & Co. Inc., Pfizer Inc., and AstraZeneca plc., covering antibodies and small molecules. Multiple ongoing Phase III trials also demonstrate continued efforts in developing these and other innovative drug modalities such as the antibody-drug conjugate. These and several other research and development initiatives represent a comprehensive approach by the companies involved, in their pursuit to addressing endometrial cancer treatment complexities and enhancing patient outcomes.
In conclusion, endometrial cancer remains a global health challenge, but recent treatment advances have improved patient outcomes compared to the previous years. Disparities in global prevalence rates and healthcare infrastructure highlight the need for tailored approaches and strong healthcare initiatives. The increase in endometrial cancer clinical trials and diverse therapeutic options reflects ongoing efforts to address endometrial cancer complexities and enhance patient well-being. Collaboration among researchers, healthcare providers, and pharmaceutical companies holds promise for further progress in endometrial cancer management and care.
Novotech has conducted over a hundred trials in Oncology, covering various indications including solid tumors. Approximately half of Novotech's projects focus on Oncology and Immuno-Oncology, bolstered by expert teams and extensive networks in the region. Novotech's longstanding relationships with investigators ensure rapid and precise site selection crucial for Oncology studies' success. With over 25 years of experience, Novotech has collaborated with numerous biotechs, delivering top-notch Oncology CRO services tailored to the needs of small to medium-sized companies.
Discover more about endometrial cancer research by downloading our comprehensive disease report.